BioTissue unveils new cryopreserved amniotic membrane solution for patients with ocular surface diseases

News
Article

The solution, CAM360 AmnioGraft, is hydrated and shelf-stable without need for refrigeration.

Closeup of inflamed eye Image Credit: AdobeStock/KryuchkaYaroslav

Image Credit: AdobeStock/KryuchkaYaroslav

BioTissue has announced the unveiling of its CAM360 AmnioGraft (CAM360 AG), which is a new, hydrated, shelf-stable cryopreserved amniotic membrane (CAM) solution that has been developed for the treatment of ocular surface disease and disorders. The solution is ideal for patients with mild to moderate dry eye disease (DED) and other ocular surface conditions, working to optimize their comfort, according to a news release.

“The introduction of CAM360 AG revolutionizes how eye care professionals can leverage regenerative medicine in the treatment of the ocular surface, particularly when it comes to dry eye disease,” said Ted Davis, president and CEO of BioTissue, in the release. “dry eye disease is a progressive disease, and until now, the lack of options available meant that practitioners often had to wait until the patient’s condition worsened before they could intervene. CAM360 AG bridges that gap, enabling practitioners to provide more patients with treatment much earlier, which is a true reflection of our dedication to improving patients’ lives with everything we do.”

The CAM360 AG works to alleviate signs and symptoms of DED, working through anti-inflammatory, anti-scarring, and anti-angiogenic actions to promote healing capabilities. Other ocular conditions that the solutions can help alleviate discomfort from include superficial punctate keratitis and neurotrophic keratitis.1

The CAM360 AG is also a ringless CAM that does not require refrigeration and includes adhesive properties so the CAM stays in place under a bandage contact lens (BCL). The solution instead has CryoTek and SteriTek preservation methods that retain HC-HA/PTX3 found in fresh tissue, which is in part responsible for amniotic membrane’s therapeutic benefits.1 These processes allow for efficient handling, storage, and product application, according to the release.

BioTissue has begun initial shipments of CMA360 AG, with nationwide availability expected by the end of June 2024.1

Reference
  1. BioTissue introduces CAM360 AmnioGraft, redefining regenerative therapy for dry eye and other ocular surface disorders. News release. BioTissue. June 3, 2024. Accessed June 7, 2024. https://biotissue.com/news/biotissue-introduces-cam360-amniograft-redefining-regenerative-therapy-for-dry-eye-and-other-ocular-surface-disorders/
Related Videos
Selina McGee, OD, FAAO, and Jessilin Quint, OD, MBA, FAAO
Selina McGee, OD, FAAO, and Jessilin Quint, OD, MBA, FAAO
Drs Erin Draper and Chris Cuk outline the important role optometrists have in spotting neurodegenerative disease in patients
Jade Coats, OD, overviews a lecture on ocular pain and patient care
Jade Coats, OD, outlines two poster presentations she gave on a novel lipid-containing eye drop at the AOA Optometry's Meeting
Adam Alexander, OD, chats with Optometry Times about his AOA e-poster presentation on Miebo
Megan Cavet, PhD
Nazlee Zebardast, MD, MSc, overviews her ARVO 2024 presentations on glaucoma and polygenic risk scores
© 2024 MJH Life Sciences

All rights reserved.